BTK and B-cell chronic lymphocytic leukemia: More particularly, the covalent-binding BTK inhibitor IBR has shown to be a potent anticancer drug in chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, and MM by interfering with B-cell homing, survival and microenvironment-mediated drug resistance [17,18,22,23,24,25].